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Blood and Marrow Transplant Program has undertaken
a Quality Improvement Retrospective Project utilizing Palli-
ative Care in the outpatient setting, to proactively address
these chronic issues. Retrospective analysis suggests imple-
mentation of early Palliative Care in this patient population
improves quality of life, while reducing costly in-patient, end
of life care.218
Feasibility of Cardiopulmonary Exercise Testing and
Longitudinal Patient-Reported Outcome (PRO)
Assessment in Patients Undergoing Hematopoietic Cell
Transplantation
William A. Wood 1, Allison M. Deal 2, Amy Abernethy 3,
Claudio Battaglini 4, Yoon Hie Kim 5, Julia Whitley 6,
Charlotte Shatten 7, Jonathan S. Serody 8, Thomas C. Shea 9,
Bryce B. Reeve 10. 1 Department of Medicine, Division of
Hematology/Oncology, Lineberger Comprehensive Cancer
Center, University of North Carolina at Chapel Hill, Chapel Hill,
NC; 2 Biostatistics Core Facility, Lineberger Comprehensive
Cancer Center, University of North Carolina at Chapel Hill;
3 Division of Medical Oncology, Duke University Medical Center,
Duke Cancer Institute; 4 Department of Exercise and Sport
Science, University of North Carolina at Chapel Hill; 5 Brody
School of Medicine, East Carolina University, Greenville, NC;
6 Lineberger Comprehensive Cancer Center, University of North
Carolina at Chapel Hill, University of North Carolina at Chapel
Hill; 7 Lineberger Comprehensive Cancer Center, University of
North Carolina at Chapel Hill; 8 Comprehensive Cancer Center,
University of North Carolina, Chapel Hill, NC; 9 Department of
Medicine, UNC Lineberger Comprehensive Cancer Center,
University of North Carolina at Chapel Hill, Chapel Hill, NC;
10 Department of Health Policy and Management, Gilllings
School of Global Public Health, University of North Carolina at
Chapel Hill
Background: Hematopoietic Cell Transplantation (HCT) is
a potentially curative therapy for high risk malignancies but
remains limited by treatment-related toxicity. Pre-HCT
cardiopulmonary exercise testing and longitudinal post-HCT
patient-reported outcome (PRO) surveillance are new tech-
niques that may help to predict risk and tailor interventions
to improve long term outcomes.
Patients and Methods: We performed a feasibility study
enrolling 32 patients into three cohorts (10 autologous HCT
recipients, 11 full intensity allogeneic HCT recipients, and 11
reduced intensity allogeneic HCT recipients). Pre-transplant
physiological measurements included VO2peak assessment by
cycle ergometer and 6-minute walk testing (6MWT). PRO
measurements included daily and weekly symptom inven-
tories derived from the NCI's PRO-CTCAE, and weekly HRQOL
assessments using the NIH's PROMIS Global Health measure.
Spearman correlation coefﬁcients, Wilcoxon Signed Rank
tests, and univariable Cox regression models were used to
determine the associations of variables with each other and
with outcomes.
Results: Median age at the time of transplantation was 57.6
years. Eighty-one percent of patients had intermediate or
advanced disease and 41% had a high school education or
lower. Pre-deﬁned feasibility criteria for enrollment (>60%)
and data collection were achieved. Ninety-one percent of
patients completed VO2peak and 6MWT prior to HCT. Ninety-
four percent of patients opted to use the electronic mode of
survey assessments. Weekly symptom surveys were
completed in a median of 4.3 minutes, and weekly HRQOL
surveys were completed in a median of 3 minutes. Themedianweekly completion rate was 100% in all cohorts from
the start of conditioning through hospital discharge. VO2peak
was positively correlated with 6MWT (r¼0.65, P < .001) and
negatively correlated with months of prior chemotherapy
(r¼-0.43, P¼ .03), and was not correlated with age or HCT-CI.
A VO2peak >16mL/kg*min (N¼21/29) was associated with
a decreased risk of mortality after HCT (HR 0.11 (0.02-0.59),
P ¼ .001). Patients with VO2peak 16mL/kg*min had higher
overall symptom scores and worse physical and mental
HRQOL at baseline and throughout the period of observation
than patients with VO2peak > 16mL/kg*min. In general,
symptoms were correlated with physical and mental HRQOL.
Individual symptoms differed in frequency and severity by
cohort and by time point, in clinically expected ways.
Statistically signiﬁcant differences were seen when
comparing all three cohorts by overall symptom scores and
by physical and mental HRQOL.
Conclusions: Pre-HCT cardiopulmonary exercise testing and
post-HCT longitudinal PRO surveillance are feasible, mean-
ingful, and potentially prognostic. These techniques should
be explored further in larger studies.219
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Introduction: HCT survivors are at risk of elevated symptom
burden. We examined demographic and treatment factors
that might predict six long-term symptoms: cancer-related
distress, depression, insomnia, fatigue, pain, and physical
limitations.
Method: Four invitations to participate were sent by email to
HCT survivors on the BMT InfoNet listserve, a patient
resource and advocacy site. Eligibility criteria included >18
years old, more than two years post-HCT, without a recur-
rence or second cancer in the prior two years, without severe
depression, able to communicate in English, and with
internet and email access. Measures were the Cancer and
Treatment Related Distress scale, the Symptom Checklist-90-
R depression, the Insomnia Symptom Questionnaire, the
Fatigue Symptom Inventory, the Brief Pain Inventory, and the
Short Form-36 physical function scale. Standardized cutoffs
were used for each measure to determine if participants had
symptoms. A sum was computed for a potential range of
scores (0-6).
Results: Of 493 registered survivors, 386 (78%) were eligible.
Participants were from the U.S. (94%, N¼361) and 12 other
countries, treated at 136 centers, largely Caucasian and non-
Hispanic (95%), on average 9 years post-HCT (SD¼6, range
2-33); 70% received allogeneic HCT, 20% were receiving
treatment for chronic graft versus host disease (cGVHD).
Mean age was 54 (SD¼12, range 19-76). Participants with
elevated scores on at least one symptom comprised just over
half of the sample (57%) and 27% reported 3 or more symp-
toms (N¼105). The least commonly endorsed symptom was
